Researchers from Bielefeld University used a single sequencing run, during installation of a Genome Sequencer FLX, to completely assemble and characterise the genome of Corynebacterium kroppenstedtii
The whole genome analysis, led by Andreas Tauch, revealed that lipophilism is the dominant feature involved in pathogenicity of the corynebacterium.
The study, entitled "Ultrafast pyrosequencing of Corynebacterium kroppenstedtii DSM44385 revealed insights into the physiology of a lipophilic corynebacterium that lacks mycolic acids" appears in the Journal of Biotechnology.
The single run with the Genome Sequencer FLX System yielded 560,248 shotgun reads with 110,018,974 detected bases that were assembled into a contiguous genomic sequence with a total size of 2,446,804bp.
Automatic annotation of the complete genome sequence and the comparative content analysis of the data revealed a large repertoire of genes involved in sugar uptake and central carbohydrate metabolism.
The study was based on a single run from the Genome Sequencer FLX System.
The platform generates 100 million bases, from 400,000 individual sequence reads of 250 bases in length, per 7.5 hour run.
These characteristics, along with high single read accuracy and paired-end reads, make the technology of 454 Sequencing the clear choice for many applications such as whole genome sequencing, as seen in this study.
The analysis corroborates the lack of corynomycolic acids as well as the lipid-requiring phenotype as the key features of C kroppenstedtii from the taxonomical viewpoint.
The lack of mycolic acids is apparently caused by the loss of a condensase gene cluster and a mycolate reductase gene, whereas the lipophilic phenotype is due the absence of a microbial type I fatty acid synthase gene.
Corynebacterium kroppenstedtii is a lipophilic corynebacterial species that lacks in the cell envelope the characteristic alpha-alkyl-beta-hydroxy long-chain fatty acids, designated mycolic acids.
C kroppenstedtii is rarely recognised in human clinical samples, but it was recovered in research samples from respiratory specimens as well as from breast tissue, pus or deep wound swaps of patients with mastitis.
454 Life Sciences, a part of Roche Applied Science, the life science unit of Roche, develops and commercialises the innovative Genome Sequencer System for ultra-high-throughput DNA sequencing.
Specific applications include de novo sequencing and re-sequencing of genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest.
The hallmarks of 454 Sequencing are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired reads.
The technology of 454 Sequencing has enabled many peer-reviewed studies in diverse research fields, such as cancer and infectious disease research, drug discovery, marine biology, anthropology, paleontology, and many more.
